Multidrug-Resistant HIV-1: Westat Helps Deliver a Treatment Option

Running out of treatment options for a disease is terrifying for any patient. For people infected with multidrug-resistant (MDR) HIV-1, a lack of treatment options often means a death sentence. But now, thanks to a clinical trial conducted by Westat, a new treatment advance is giving these patients fresh hope.

The drug is Trogarzo™, an infusible agent that blocks HIV from infecting certain immune cells while preserving normal immunological functions. Trogarzo was introduced to Westat in 2015 under its original name, ibalizumab, when our company was tapped to conduct the phase 3 registration trial of it.

Facilitating an expedited review

Because of the seriousness of MDR HIV-1 and the lack of treatment options for it, the Food and Drug Administration (FDA) had assigned “orphan drug status” and “breakthrough therapy” designation to ibalizumab. Put on a fast track, Westat prepared to work swiftly to establish the drug’s safety and effectiveness through well-controlled studies.

We worked aggressively—focusing on enrollment of eligible participants and quick qualification of new sites authorized to administer the drug to participants in dire need of it. We formed a central hub with the sites and with qualified labs. In less than 3 years, precisely following the required FDA clinical trial process, we completed the phase 3 trial. Our next steps were to integrate data from the phase 2b study into the phase 3 study and author the clinical study report for submission of the Biologics Licensing Application to the FDA.

What did the study show?

Trogarzo proved to be beneficial to MDR HIV-1 patients. It inhibited HIV cell entry and suppressed the HIV viral load below the level of detection when combined with an optimized background regimen of anti-HIV agents.

Trogarzo goes to market

On March 6, 2018, the FDA gave Trogarzo the green light to be marketed in the U.S. Today, Trogarzo is recognized as the first of a new class of antiretroviral medications to stop the progression of HIV in MDR HIV-1-infected individuals. Its novel mechanism of action has proven to be a critical new treatment advance for MDR HIV-1-infected patients seeking a last-resort therapy.

We worked aggressively and very carefully on this study. Our phase 3 work demonstrated Trogarzo’s significant antiviral activity in patients with MDR HIV-1 infection. It offered these patients a last-resort therapy.

- Nancy L. Dianis, Westat Vice President & Study Area Director, Clinical Trials Research

78%
25 weeks into study
Patients who had taken ibalizumab with a background antiretroviral therapy regimen showed a significant decrease in viral load

Want to work with us?
You’ll be in great company.

About Us Careers

Westat Employees.
Westat Employee.
Client List
Centers for Disease Control and Prevention
Centers for Medicare & Medicaid Services
Internal Revenue Service
National Science Foundation
Social Security Administration
U.S. Department of Agriculture
U.S. Department of Education
U.S. Department of Justice
U.S. Department of Transportation
U.S. Department of Veterans Affairs
Georgia Department of Transportation
Maryland Cancer Registry
Michigan Department of Health and Human Services
Texas Education Agency
Baltimore Metropolitan Council
Chicago Metropolitan Agency for Planning
DC Public Schools
NYC Mayor’s Office for Economic Opportunity
Organization for Economic Cooperation and Development
AAA Foundation for Traffic Safety
ClearWay Minnesota
Robert Wood Johnson Foundation
Teach for America
The Verizon Foundation
The Johns Hopkins University
University of Denver
University of Maryland Baltimore Campus
University of Michigan
SiriusXM
Toyota
U.S. Department of Health and Human Services
Substance Abuse and Mental Health Services Administration
The National Institutes of Health
Forbes 2019: The Best Employers for Diversity

Westat is an Equal Opportunity Employer and does not discriminate on the basis of race, creed, color, religion, sex, national origin, age, veteran status, disability, marital status, sexual orientation, citizenship status, genetic information, gender identity, or any other protected status under applicable law. Notices to Employees & Applicants.